Brett Hewlett - Comvita New CEO

CVNZF -- USA Stock  

USD 1.98  0.34  20.73%

Mr. Brett Donald Hewlett is appointed as Acting Executive Director of the Company., effective 30 September 2019. He was Chief Executive Officer of the Company., effective October 5, 2015. He is a current member of the New Zealand Trade and Enterprise Better by Design Advisory Board and an Independent Director of the USbased specialty medical device and pharmaceutical company Derma Sciences Inc. Brett holds significant international business development experience, including roles in emerging and developed markets. He previously served 15 years of a 20year career internationally with worldleading food packaging company, Tetra Pak. For five years he served as regional Managing Director of Tetra Paks eastern Mediterranean markets. Prior to that Brett worked as Commercial Director for Tetra Pak in Saudi Arabia and has also held other commercial and project management positions in the UK and Europe. He has run his own strategy consulting company and was an active angel investor supporting startup companies in New Zealand. Brett has a Bachelor of Food Technology degree from Massey University and a Masters of Business Administration from IMD in Switzerland.
Age: 51  CEO Since 2017      
64 7 533 1426

Brett Hewlett Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (1.55) % which means that it has lost $1.55 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (15.27) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 66.23 M in total debt with debt to equity ratio (D/E) of 57.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Comvita New Zealand has Current Ratio of 5.13 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 12 records

CEO Since

Murray KesslerPerrigo Company Plc
Christophe WeberTakeda Pharmaceutical Company L
Neil SwiftTakeda Pharmaceutical Company L
Heather BreschMylan NV
Gianni ZampieriVIFOR PHARMA AG
John ChiminskiCatalent
Uwe RohrhoffPerrigo Company Plc
Patricia AndrewsSumitomo Dainippon Pharma Ltd
Sigurdur OlafssonHikma Pharmaceutical
Mark TimneyThe Medicines Company
Michael RayaHikma Pharmaceutical

Entity Summary

Comvita Limited, together with its subsidiaries, manufactures, markets, and distributes natural health products. Comvita Limited was founded in 1974 and is based in Te Puke, New Zealand. Comvita New operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange.Comvita New Zealand Ltd [CVNZF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Comvita New Zealand Leadership Team

Sarah Ottrey, Independent Director
Ben Shaw, Chief Marketing Officer
Paul Reid, Director
Roy Ong, Chief Marketing Officer
Patrick Brus, Chief Corporate Services Officer
Lucas Bunt, Independent Director
Sharon Hollenstein, Chief Innovation Officer
Julianne Keast, Acting CFO
Thomas Cullwick, Independent Director
Kate Selway, Acting Chief People and Culture Officer
Edward Quilty, Non-Executive Director
RalfChristian Schlothauer, Chief Technical Officer
Julie Chadwick, Corporate Communications Manager
Simon Pothecary, Chief Sales Officer
Alan Bougen, Non-Executive Deputy Chairman of the Board
Maurice Prendergast, Independent Director
Scott Coulter, Deputy CEO, COO
Saada McNamee, Chief People and Culture Officer
Murray Denyer, Independent Director
Brett Hewlett, CEO
Mark Sadd, Chief Commercial Officer
Neil Craig, Non-Executive Independent Chairman of the Board
MBA DipT, Chief Supply Chain Officer
Sarah Kennedy, Independent Director
Colin Baskin, Chief Supply Chain Officer

Stock Performance Indicators

Current Sentiment - CVNZF

Comvita New Zealand Investor Sentiment

Macroaxis portfolio users are unresponsive in their opinion about investing in Comvita New Zealand Ltd. What is your opinion about investing in Comvita New Zealand Ltd? Are you bullish or bearish?
50% Bullish
50% Bearish

Comvita New Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Comvita New and Takeda Pharmaceutical. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Balance Of Power module to check stock momentum by analyzing balance of power indicator and other technical ratios.